Niagen Bioscience: A Great Company Suffering From Stock Dilution
Niagen Bioscience (NASDAQ:NAGE) has a debt-free balance sheet and Q2 beat show momentum—but heavy share dilution and a price ~133% above my DCF give the stock a hold rating.
Niagen Bioscience (NASDAQ:NAGE) has a debt-free balance sheet and Q2 beat show momentum—but heavy share dilution and a price ~133% above my DCF give the stock a hold rating.